Ładuje się......
Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
The development of immune checkpoint inhibitors (ICI) represents a major milestone in immune‐oncology. Over the years these agents have demonstrated efficacy in an increasing array of malignancies. Despite this success however, significant challenges remain. Novel approaches to both drug development...
Zapisane w:
| Wydane w: | Br J Clin Pharmacol |
|---|---|
| Główni autorzy: | , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
John Wiley and Sons Inc.
2020
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444803/ https://ncbi.nlm.nih.gov/pubmed/32394468 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14355 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|